LCSG - formerly LCS Golf (fka LCSG)

[jmhollen]

Shinn Capital Group Grants Two Licenses 18 Mar 2002, 1:46pm ET

HONOLULU--(BUSINESS WIRE)--March 18, 2002--Shinn Capital Group, Inc. (SCG), a Hawaii based corporation, recently granted two licenses to work with its immunostimulant Tubercin. SCG has the exclusive worldwide rights for this compound developed and administered in South Korea for the last 14 years.

It is the intent of SCG and the licensees to bring Tubercin, an immunostimulant that combats diseases such as Cancer, Aids and Arthritis, to the world markets through a variety of delivery methods. Tubercin was invented by Dr. Tai-Ho Chung of Kyungpook National University Medical School, Taegu, Korea. Tubercin is patented in the US, Japan and Korea (US Patent 6,274,356).

T-19 Incorporated (OTCBB:LCSG) was granted a license to develop products for the worldwide retail and holistic marketplaces as well as the implementation of off shore clinics; and is currently working on a Nasal Spray that appears promising and should be available in the immediate future.

Hard-To-Treat Diseases Inc. (HTTD), a wholly owned subsidiary of Gatlin Holdings, Inc. (OTCBB:GTNH) was granted a license to develop products for the Federal Drug Administration regulated marketplace as well as seek FDA approval.

Shinn Capital Group, Inc. is very supportive of both HTTD and T-19 in their missions to make Tubercin available as quickly as possible to those who seek help. SCG is a privately held investment group with close ties to the South Korean medical community.

CONTACT: SCG, Honolulu

Ronald Shinn, 808/523-5800 or toll-free 866/523-5800

.